Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Change in Cash (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Change in Cash for 8 consecutive years, with -$73.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Cash fell 3.72% year-over-year to -$73.1 million, compared with a TTM value of -$242.5 million through Sep 2025, down 176.08%, and an annual FY2024 reading of $353.1 million, up 88.0% over the prior year.
  • Change in Cash was -$73.1 million for Q3 2025 at Bicycle Therapeutics, down from -$71.5 million in the prior quarter.
  • Across five years, Change in Cash topped out at $504.4 million in Q2 2024 and bottomed at -$86.5 million in Q1 2025.
  • Average Change in Cash over 5 years is $27.0 million, with a median of -$22.3 million recorded in 2022.
  • The sharpest move saw Change in Cash tumbled 1319.67% in 2022, then skyrocketed 2154.88% in 2023.
  • Year by year, Change in Cash stood at $179.2 million in 2021, then plummeted by 112.46% to -$22.3 million in 2022, then tumbled by 104.63% to -$45.7 million in 2023, then soared by 75.16% to -$11.3 million in 2024, then tumbled by 544.74% to -$73.1 million in 2025.
  • Business Quant data shows Change in Cash for BCYC at -$73.1 million in Q3 2025, -$71.5 million in Q2 2025, and -$86.5 million in Q1 2025.